Search Results

BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today provided a business update and reported results for the year ended December 31, 2023.

BeyondSpring Inc. announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission on April 29, 2024.

BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”) today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at 10:00 a.m. ET.

BeyondSpring Inc. announced that on February 20, 2024, the Company received a written notification on minimum bid price compliance from The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550.

BeyondSpring Inc. announced that it hosted a virtual Research and Development Day to discuss its lead asset Plinabulin, a dendritic cell maturation agent, in drug combinations to potentially address the current unmet medical needs in cancer indications where patients failed prior PD-1/PD-L1 inhibitors, as well as updates for SEED Therapeutics which focuses on target protein degradation platform for innovative molecular glue drug discovery on May 15, 2024.

BeyondSpring Inc. announced that on January 4, 2024, it received a Foreign Delinquency Compliance Plan Alert Letter from The Nasdaq Stock Market LLC.